Mild to moderate inhibitors of CYP3A4 (such as amiodarone) are predicted to increase
eplerenone levels, which increases the risk of hyperkalaemia.
It is generally recommended that the dose of
eplerenone should not exceed 25 mg daily in patients taking
amiodarone. Note that hypokalaemia can exacerbate the QT-prolonging effects of
amiodarone.